Robert E. Landry

2019

In 2019, Robert E. Landry earned a total compensation of $7.9M as Executive Vice President, Finance and Chief Financial Officer at Regeneron Pharmaceuticals, a 15% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$811,395
Option Awards$3,526,669
Salary$730,000
Stock Awards$2,840,008
Other$23,470
Total$7,931,542

Landry received $3.5M in option awards, accounting for 44% of the total pay in 2019.

Landry also received $811.4K in non-equity incentive plan, $730K in salary, $2.8M in stock awards and $23.5K in other compensation.

Rankings

In 2019, Robert E. Landry's compensation ranked 1,106th out of 13,971 executives tracked by ExecPay. In other words, Landry earned more than 92.1% of executives.

ClassificationRankingPercentile
All
1,106
out of 13,971
92nd
Division
Manufacturing
384
out of 5,701
93rd
Major group
Chemicals And Allied Products
114
out of 2,200
95th
Industry group
Drugs
90
out of 1,886
95th
Industry
Pharmaceutical Preparations
68
out of 1,398
95th
Source: SEC filing on April 24, 2020.

Landry's colleagues

We found four more compensation records of executives who worked with Robert E. Landry at Regeneron Pharmaceuticals in 2019.

2019

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer

2019

George Yancopoulos

Regeneron Pharmaceuticals

Chief Scientific Officer

2019

Andrew Murphy

Regeneron Pharmaceuticals

Executive Vice President, Research

2019

Daniel Van Plew

Regeneron Pharmaceuticals

Executive Vice President and General Manager, Industrial Operations and Product Supply

News

You may also like